Dose escalation of aspirin in certain splenectomized thalassemic patients could potentially overcome aspirin resistance, and subsequently lower the incidence of future thromboembolic events. aspirin, aspirin resistance, thromboembolic event, splenectomized thalassemic patients
Conditions
Interventions
This study enrolled 53 splenectomized thalassemic patients who had been receiving aspirin at a dosage of 81 mg/day for at least 3 months. Baseline blood tests were performed to assess aspirin resistan
Experimental Drug
Aspirin
Sponsors
-
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Thalassemia patient confirmed by Hb typing or molecular testing, 2.Continuous ASA 81 mg/day at least 3 months, 3.Post splenectomy
Exclusion criteria
Exclusion criteria: 1.Coadministration with any other antiplatelets/anticoagulants, 2.Risk factors affecting thromboembolic event, 2.1comorbidity with other causes of platelet dysfunction; not from thalassemia, 2.2continuous contraceptive drugs, 3.Risk factors for GI bleeding, 3.1major surgical procedure within 1 month before enrollment, 3.2history of abnormal bleeding, 3.3platelet < 100,000 cells/cu.mm., 3.4active malignancy, 4.Active critical illness/ infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aspirin resistance at 12 months after end of the intervention 1. LTA: platelet aggregation to arachidonic acid at least 20% 2. PFA-200: a collagen/epinephrine (CEPI) closure time less than 165 seconds 3. Serum TXB2 more than 0.69 ng/mL. | — |
Secondary
| Measure | Time frame |
|---|---|
| Factors associated with aspirin resistance at 12 months after end of the intervention Potential universal confounders and other laboratory parameters, including D-dimer and ferritin, were evaluated. | — |
Countries
Thailand
Contacts
Public ContactKoraphat Suepkhruea
Faculty of Medicine, Chiang Mai University
Outcome results
None listed